Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feldman, A. L.
Right arrow Articles by Libutti, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feldman, A. L.
Right arrow Articles by Libutti, S. K.

Annals of Surgical Oncology, Vol 6, Issue 6 562-567, Copyright © 1999 by Society of Surgical Oncology

ARTICLES

Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma

A. L. Feldman, H. R. Alexander Jr, D. L. Bartlett, D. L. Fraker and S. K. Libutti
Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.

BACKGROUND: Despite high rates of complete responses (CRs) to isolated limb perfusion (ILP) for patients with in-transit melanoma (60% to 90%), extremity recurrences are common. We evaluated our experience with managing these recurrences to determine how best to treat these patients. METHODS: Between April 1992 and April 1998, 72 patients experienced CRs after hyperthermic ILP using Melphalan, with (n = 46) or without (n = 26) tumor necrosis factor. Of these, 25 patients (35%) experienced initial recurrences in the extremities, and they form the basis of this study. RESULTS: Three patients who underwent repeat ILP for treatment of their recurrences experienced a second CR and recurrence in the extremity (at 9, 15, and 16 months), allowing analysis of 28 cases. For 5 of 20 recurrences managed with excision, 2 of 6 managed with repeat ILP, and 0 of 2 managed with systemic treatment, the patient was free of disease at the last follow-up examination (median follow-up period, 11 months). CONCLUSIONS: Isolated extremity recurrences after CRs to ILP occurred in 35% of patients. Initially, these could be managed successfully by excision or repeat ILP for the majority of patients (92%). We recommend excision of small-volume recurrent disease, reserving repeat ILP for patients with increasing numbers of lesions or increasing rapidity of in-field recurrences.


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
D. J. Grunhagen, B. van Etten, F. Brunstein, W. J. Graveland, A. N. van Geel, J. H. W. de Wilt, and A. M. M. Eggermont
Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor {alpha} and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion Failure
Ann. Surg. Oncol., August 1, 2005; 12(8): 609 - 615.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
E. M. Noorda, B. Takkenberg, B. C. Vrouenraets, O. E. Nieweg, B. N. van Geel, A. M. M. Eggermont, G. A. M. Hart, and B. B. R. Kroon
Isolated Limb Perfusion Prolongs the Limb Recurrence-Free Interval After Several Episodes of Excisional Surgery for Locoregional Recurrent Melanoma
Ann. Surg. Oncol., May 1, 2004; 11(5): 491 - 499.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the Society of Surgical Oncology.